Test how skin scores change in cutaneous dermatomyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This study looks at how well skin symptoms improve in adults with cutaneous dermatomyositis by using a specific skin-scoring tool. The results may help doctors better measure treatment response and guide care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 years or older).
- You must have a confirmed diagnosis of cutaneous dermatomyositis (a skin form of dermatomyositis).
- You must be able to understand the study and give informed consent.
- You must not have dermatomyositis without the skin involvement—cutaneous dermatomyositis is required.
- You cannot be a current employee or student at the University of Pennsylvania.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a type of skin inflammation called panniculitis that can happen in people with dermatomyositis. The goal is to learn more about this condition so that better treatments can be developed.
This study looks at how severe dermatomyositis is in people who develop it as children or adults. It aims to better understand the disease and may help guide future treatments.
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
This trial tests an investigational drug called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rashes. The goal is to see if the drug can help control the disease.
This study uses a special imaging technique (photoacoustic/ultrasound) to look at calcium deposits under the skin in people with dermatomyositis. It aims to find patterns that help doctors understand the condition and track how well treatments work.
This Phase 3 study tests whether interleukin-2 can better control “active” dermatomyositis, an inflammatory muscle and skin disease. Participants will be monitored to see if treatment improves disease activity and symptoms.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.